Floatz logo

STAPULDENCEL

Ovarian Neoplasms

SOTIO a.s.Cell therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
73/ 100

Competitive context

79 Active assets in the Ovarian Neoplasms cohort.

Asset / SponsorPhaseRating
Inno-206
GlaxoSmithKline
Phase 4BBB
gw786034
The Christie NHS Foundation Trust
Phase 2BB
Carboplatin
Eli Lilly and Company
Phase 3BB
tlk286
Telik
Phase 3BB
Niraparib
GlaxoSmithKline
Phase 4BB

View all 50 →

Same molecule, other indications

STAPULDENCEL is also rated in:

ovarian carcinomaDormant
B
Indicative ·
62 / 100
View asset →
peritoneal carcinomaDormant
B
Indicative ·
60 / 100
View asset →
metastatic prostate carcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →